Current Support
- Integrated Technology Resource for Biomedical Glycomics (P.I.); National Center
for Resource Resources (NIH); 7/1/03 – 6/30/08; $ 6.7 million total costs.
- Structural characterization of GlcNAc-T V (with J. Prestegard); National Cancer
Institute program for Molecular Targets for Cancer Therapetutics; 4/1/02 –
3/31/05, $200,000 Direct Costs/year.
- GlcNAc-T V Regulation of Cell Surface Structure/Function; National Cancer
Institute; 6/1/01 – 5/30/05; Direct costs, $246,750/year.
- Inhibitors of alpha-mannosidase II as potential cancer therapeutics
(Investigator; P.I., K. Moremen); National Cancer Institute; 9/1/02-8/25/07;
$315,000 Direct Costs/year.
- Oligosaccharides and Lectins in Xenopus laevis
development, component of NIH Biomedical Complex Carbohydrate Resource
Center, 10/1/99 - 9/30/04; $60,000 Direct Costs/year.
Pending Support
- Cancer Glycobiology (P.I.) Application of the East Georgia Cancer Center
of Excellence to the Georgia Cancer Coalition 7/1/03—6/30/06; $600,000 direct costs
|
